InvestmentsJul 11 2016

Fund Review: Axa Framlington Biotech

twitter-iconfacebook-iconlinkedin-iconmail-iconprint-icon
Search supported by

This £527m fund seeks long-term capital appreciation by investing in companies within biotechnology, genomic and medical research industries worldwide, according to manager Linden Thomson.

For unlimited access to FTAdviser content...

Register now for free

  • Read the latest news and views from the world of financial advice
  • Never miss a story - sign up to our email alerts
  • Bank CPD while you read
Have an account? Sign In